MYD88 and lymphoma: Mutational profile in lymphomas of immune-privileged sites includes concomitant MYD88 and CD79B mutations with genomic signature C5/MCD/MYD88 and genetic inactivation of MHC class I and II and β2-microglobulin with subsequent loss of protein expression [2].